Page last updated: 2024-08-21

quinazolines and pipobroman

quinazolines has been researched along with pipobroman in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (22.22)	18.2507
2000's	5 (55.56)	29.6817
2010's	1 (11.11)	24.3611
2020's	1 (11.11)	2.80

Authors

Authors	Studies
Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ	1
Silverstein, MN; Tefferi, A	1
Hehlmann, R; Lengfelder, E	1
Briere, J; Guilmin, F	1
Bangerter, M; Griesshammer, M; Grünewald, M	1
Griesshammer, M; Langer, C	1
Reilly, JT	1
Newberry, KJ; Sever, M; Verstovsek, S	1
Besses, C; Blau, IW; Dong, T; Durrant, S; Francillard, N; Griesshammer, M; Harrison, CN; Hino, M; Kiladjian, JJ; Kirito, K; Masszi, T; Mesa, R; Miller, CB; Moiraghi, B; Pane, F; Passamonti, F; Rosti, V; Rumi, E; Vannucchi, AM; Verstovsek, S; Wroclawska, M; Zachee, P	1

Reviews

7 review(s) available for quinazolines and pipobroman

Article	Year
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leukemia & lymphoma, 1996, Volume: 22 Suppl 1 Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; Busulfan; Female; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Incidence; Interferon-alpha; Ischemic Attack, Transient; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	1996
Treatment of polycythaemia vera and essential thrombocythaemia. Bailliere's clinical haematology, 1998, Volume: 11, Issue:4 Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Thrombosis	1998
[Polycythemia vera: current status of therapy]. Deutsche medizinische Wochenschrift (1946), 2000, Oct-13, Volume: 125, Issue:41 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Middle Aged; Phlebotomy; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Thromboembolism	2000
Management of patients with essential thrombocythemia: current concepts and perspectives. Pathologie-biologie, 2001, Volume: 49, Issue:2 Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Progression; Female; Hemorrhagic Disorders; Humans; Hydroxyurea; Interferons; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Quinazolines; Risk; Safety; Thrombocythemia, Essential; Thrombophilia	2001
Current treatment practice for essential thrombocythaemia in adults. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:3 Topics: Adult; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Prognosis; Quinazolines; Thrombocythemia, Essential	2001
Pharmacotherapy of essential thrombocythaemia: economic considerations. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:9 Topics: Age Factors; Antineoplastic Agents; Aspirin; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Quinazolines; Risk Factors; Thrombocythemia, Essential	2003
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leukemia & lymphoma, 2014, Volume: 55, Issue:12 Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2014

Trials

1 trial(s) available for quinazolines and pipobroman

Article	Year
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. The Lancet. Haematology, 2020, Volume: 7, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Nitriles; Pipobroman; Polycythemia Vera; Polyethylene Glycols; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Survival Rate; Time Factors	2020

Article

Year

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

The Lancet. Haematology, 2020, Volume: 7, Issue:3

Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Nitriles; Pipobroman; Polycythemia Vera; Polyethylene Glycols; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Survival Rate; Time Factors

2020

Other Studies

1 other study(ies) available for quinazolines and pipobroman

Article	Year
Practical approach to treating essential thrombocythaemia: case studies. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; Middle Aged; Pipobroman; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Warfarin	2007